Inclusion Criteria:

- Histologically confirmed cutaneous or mucosal melanoma, meeting criteria for 1 of the
following:

- Unresectable stage III disease (locally relapsed unresectable, in-transit lesions, or
unresectable draining nodes)

- Stage IV disease, metastatic to 1 of the following sites:

- Skin, subcutaneous tissues, or distant lymph nodes

- Lung

- Other visceral sites with lactic dehydrogenase ≤ 2 times upper limit of normal
(unless due to liver stasis)

- De novo metastatic disease allowed provided patient refused any standard or approved
stage-appropriate therapy for melanoma

- Measurable disease

- HLA-A2.1 positive (HLA-A*0201 by molecular subtyping)

- MART-1-expressing tumor by reverse transcription polymerase chain reaction or
immunohistochemistry

- No symptomatic brain metastases and/or progression of CNS metastases within the past
4 weeks

- Age 18 and over

- Performance status ECOG 0-1 OR

- Karnofsky 70-100%

- HIV negative

- Negative pregnancy test

- Fertile patients must use effective barrier contraception during and for 3 months
after study participation

- More than 30 days since prior immunotherapy for metastatic, relapsed, or primary
melanoma

- More than 30 days since prior chemotherapy for metastatic, relapsed, or primary
melanoma

- More than 4 weeks since prior corticosteroids

- More than 30 days since prior radiotherapy for metastatic, relapsed, or primary
melanoma

- More than 30 days since prior surgery for metastatic, relapsed, or primary melanoma.

- More than 30 days since other prior therapy for metastatic, relapsed, or primary
melanoma

- More than 14 days since prior anti-infective therapy

- More than 4 weeks since prior immune suppressive therapy (e.g., cyclosporine)

Exclusion Criteria:

- chronic hepatitis B or C

- asthma

- inflammatory bowel disease

- celiac disease

- history of chronic colitis or other chronic gastrointestinal conditions associated
with diarrhea or bleeding

- active chronic inflammatory or autoimmune disease, including any of the following:

- Psoriasis

- Rheumatoid arthritis

- Multiple sclerosis

- Hashimoto's thyroiditis

- Addison's disease

- Graves' disease

- Systemic lupus erythematosus

- active infection OR fever over 100° F within the past 3 days

- allergy to study drugs

- pregnant

- symptomatic seizures

- other medical problem that would preclude study participation

- prior melanoma immunotherapy containing MART-1 antigen

- prior anti-T-cell therapy

- prior anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody
(CP-675,206)

- organ allografts requiring long-term immune suppressive therapy